Wang Xiaofei, Wang Zhigang, Wang Chengwei, Ji Yong, Ding Xuan, Zang Yizheng
Shandong University, The Second Hospital, Department of Neurosurgery, Jinan 250003, Shandong, China.
Turk Neurosurg. 2016;26(1):69-76. doi: 10.5137/1019-5149.JTN.13350-14.1.
We assessed the safety and effectiveness of the Enterprise stent in treating atherosclerotic intracranial arterial stenosis (AIAS).
This was a retrospective study conducted with 60 consecutive patients with 62 AIAS lesions who received the Enterprise stent at the Department of Neurosurgery, Second Hospital of Shandong University between June 2012 and January 2014. All patients were assessed using the modified Rankin scoring system at discharge. Clinical follow-ups and digital subtraction angiography (DSA) were performed at 1, 3, 6 and 12 months postoperatively.
There were 42 men and 18 women with a mean age of 56.8 ± 8.0 years. Fourteen lesions (22.6%) were at the anterior and 48 (77.4 %) were at the posterior circulation. The mean stenosis rate was 76.3 ± 12.7%. The mean stenotic vessel length was 7.7 ± 2.0 mm. The technical success rate was 100%. The mean post-stent residual stenosis rate was 22.8 ± 4.8%. Five patients (8.3%) had perioperative complications, but no disability or mortality occurred within 30 days. The mean follow-up duration was 6.2 months. DSA was used to evaluate 45 lesions (72.6%) six months postoperatively: 6 (13.3%) had postoperative restenoses, 2 at the anterior circulation, and 4 at the posterior circulation. Of these 6, 4 (66.7%) were immediate residual stenoses after stenting. The residual stenosis rate was identified as a risk factor for restenosis. Five (8.3%) ischemic events, consistent with the vascular lesions, occurred.
Application of the Enterprise stent was safe and efficacious. The technical success rate was high while the perioperative complication rate was low.
我们评估了Enterprise支架治疗颅内动脉粥样硬化性狭窄（AIAS）的安全性和有效性。
这是一项回顾性研究，对2012年6月至2014年1月期间在山东大学第二医院神经外科接受Enterprise支架治疗的60例连续患者的62处AIAS病变进行了研究。所有患者出院时均采用改良Rankin评分系统进行评估。术后1、3、6和12个月进行临床随访和数字减影血管造影（DSA）。
患者中男性42例，女性18例，平均年龄56.8±8.0岁。14处病变（22.6%）位于前循环，48处（77.4%）位于后循环。平均狭窄率为76.3±12.7%。平均狭窄血管长度为7.7±2.0mm。技术成功率为100%。支架置入后平均残余狭窄率为22.8±4.8%。5例患者（8.3%）出现围手术期并发症，但30天内无残疾或死亡发生。平均随访时间为6.2个月。术后6个月采用DSA评估45处病变（72.6%）：6处（13.3%）出现术后再狭窄，前循环2处，后循环4处。在这6处病变中，4处（66.7%）为支架置入后即刻残余狭窄。残余狭窄率被确定为再狭窄的危险因素。发生了5例（8.3%）与血管病变相符的缺血事件。
Enterprise支架的应用安全有效。技术成功率高，围手术期并发症发生率低。
